RNA-UTPase 1: A Potential Drug Target for Various Diseases (G353091)

Target Name: RAET1G

NCBI ID: G353091

RAET1G

RNA-UTPase 1: A Potential Drug Target for Various Diseases

RAET1G (uridine triphosphate deaminase-1 gene) is a gene that encodes a protein known as RNA-uridine triphosphate deaminase 1 (RNA-UTPase 1). This gene is located on chromosome 18 and has been implicated in the development and progression of various diseases, including cancer.

One of the key functions of RNA-UTPase 1 is to regulate the levels of uracilic acid in the cytoplasm of cells. Uracilic acid is a byproduct of DNA replication and can accumulate in the cytoplasm, leading to cell death and a variety of cellular responses. RNA-UTPase 1 helps to maintain a delicate balance of uracilic acid levels by continuously breaking down and removing uracilic acid from the cytoplasm.

In addition to its role in cell signaling, RNA-UTPase 1 has also been shown to play a key role in the development and progression of cancer. Many studies have suggested that high levels of uracilic acid in the cytoplasm of cancer cells may contribute to the development of these deadly diseases.

Furthermore, RNA-UTPase 1 has also been linked to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells and can lead to a range of cognitive and behavioral symptoms.

The search for new drug targets and biomarkers has led to the investigation of RNA-UTPase 1. Researchers have been interested in using RNA-UTPase 1 as a potential drug target because of its unique structure and the role it plays in various cellular processes.

One approach to targeting RNA-UTPase 1 is to use small molecules that can modulate its activity. This strategy has been used to develop a variety of drugs that have been shown to act on RNA-UTPase 1 and are being tested in clinical trials for various diseases.

Another approach to targeting RNA-UTPase 1 is to use antibodies that can specifically recognize and target the protein. This strategy has been used to develop a variety of antibodies that have been shown to block the activity of RNA-UTPase 1 and are being tested in clinical trials for various diseases.

In conclusion, RAET1G (uridine triphosphate deaminase-1 gene) is a gene that has been implicated in the development and progression of various diseases. Its unique structure and role in cell signaling have made it an attractive target for drug development. The use of small molecules and antibodies to modulate and block the activity of RNA-UTPase 1 is an promising strategy for the development of new treatments for a variety of diseases.

Protein Name: Retinoic Acid Early Transcript 1G

Functions: Binds and activates the KLRK1/NKG2D receptor, mediating natural killer cell cytotoxicity

The "RAET1G Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAET1G comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets